Reduction of leukocyte-derived H₂S linked to abnormal glycolipid metabolism in hypertensive subjects

ABSTRACT

We deduced that leukocyte-derived H₂S would also play a pivotal role regarding nutrition homeostasis in hypertensive subjects. Plasma was obtained from patients with hypertension (n  =  151) as well as control (n  =  41). Leukocyte-derived H₂S speed was determined, and biochemical indices of glucose and lipid metabolism were measured. Western blot analyses of CSE were also performed. Inflammation factors were measured. Leukocyte-derived H₂S is produced at a significantly lower rate in overweight or obese patients (p < 0.05). There is a significant negative correlation between H₂S and the levels of HOMA-RI and insulin in overweight patients and has a positive relationship with HDL-C only in overweight hypertensive patients (p < 0.05). Patients with high insulin levels showed down-regulation of CSE (p < 0.05). The levels of IL-10 decreased in both the obese and the overweight which showed significant relationship with all metabolism parameters such as HDL-C(r = 0.176, p = 0.031), insulin (r = −0.181, p = 0.027), HOMA-IR (r = −0.166, p = 0.045), and H₂S speed (r = 0.995, p = 0.001). Linear regression analysis showed that insulin levels will increase (β = −1.685, p = 0.041) with the slower speed of H₂S. Leukocyte-derived H₂S production varied according to the nutritional status of hypertensive subjects, and the H₂S/IL-10 signaling pathway may be the junction point among hypertension, disturbance of nutritional status, and inflammation.

KEYWORDS:

• Glycolipid metabolism
• hypertension
• inflammation
• leukocyte-derived H₂S

Acknowledgments

I would like to extend my sincere gratitude to professor Xue Changyong, for his instructive advice and useful suggestions on my thesis. Second, I would like to express my heartfelt gratitude to Professor Geng Bin, who gave me great help and support in the experiment.

Conflict of interest

The authors declare no conflict of interest.

Funding

Funding was provided by the National Central Healthcare Fund of China (W2013DJ15).

Additional information

Funding

Funding was provided by the National Central Healthcare Fund of China (W2013DJ15).